Translation News and Research

RSS

Ribosomal proteins RPL5, RPL11 play essential role in normal cell proliferation

Researchers from the Laboratory of Cancer Metabolism (LCM) led by George Thomas at the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Division of Hematology/ Oncology, University of Cincinnati, have shown that loss of either one of two tumor suppressors, ribosomal proteins RPL5 or RPL11, fail to induce cell-cycle arrest, but prevent the proliferation of cells as they have a reduced capacity to synthesize proteins.

12 Dec 2013

New Journal presents techniques for finding new uses for approved drugs

Mary Ann Liebert, Inc., publishers is pleased to announce Drug Repurposing, Rescue, and Repositioning, a dynamic new peer-reviewed journal that will present techniques and tools for finding new uses for approved drugs—particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.

12 Dec 2013

NIH data-sharing may advance genetic and translational research, therapeutic target discovery

For the first time, large-scale information on the biochemical makeup of small interfering RNA (siRNA) molecules is available publicly. These molecules are used in research to help scientists better understand how genes function in disease.

12 Dec 2013

Viewpoints: Optimism about Obamacare; 834 errors; can-you-keep-your-doctor debate

This was the week when liberals decided that it was safe to feel optimistic about Obamacare again. ... A worst-case scenario, in which the website remained unusable well into the new year, seems to have been averted, and with it the danger that insurers or Congressional Democrats would begin to bail on Obamacare entirely.

10 Dec 2013

Scientists target protein-detection approach to systematically measure human repertoire of proteins

An international team of scientists led by Fred Hutchinson Cancer Research Center cancer proteomics expert Amanda Paulovich, M.D., has demonstrated the feasibility of large-scale, standardized protein measurements, which are necessary for validation of disease biomarkers and drug targets.

9 Dec 2013

Finding identifies new mechanism that could contribute to the pathology of ALS

RNA molecules, used by cells to make proteins, are generally thought to be "silent" when stowed in cytoplasmic granules. But a protein mutated in some ALS patients forms granules that permit translation of stored RNAs, according to a study in The Journal of Cell Biology. The finding identifies a new mechanism that could contribute to the pathology of the disease.

4 Dec 2013

Study identifies high burden of pain in older adults

More than half of older adults in the United States - an estimated 18.7 million people - have experienced bothersome pain in the previous month, impairing their physical function and underscoring the need for public health action on pain. Many of those interviewed by investigators for a study published in the current issue of PAIN- reported pain in multiple areas.

3 Dec 2013

Enzyme intervenes when cancer-fighting PTEN is bound for cell's protein-destroying machinery

A protector for PTEN, a tumor-thwarting protein often missing in cancer cells, has emerged from research led by scientists at The University of Texas MD Anderson Cancer Center published online at Nature Cell Biology this week.

28 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Research: Human neural stem cells could improve blood flow in critical limb ischemia

New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels. Critical limb ischemia is a disease that severely obstructs arteries and reduces the blood flow to legs and feet. CLI remains an unmet clinical problem and with an ageing population and the rise in type II diabetes, the incidence of CLI is expected to increase.

27 Nov 2013

SIMM and Crown Bioscience collaborate to build MCT center in China

Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS) and Crown Bioscience, Inc., announced today that they have reached an agreement to form a strategic collaboration focused on translational oncology and to join forces to build a mouse clinical trial (MCT) center at Crown Taicang campus, Taicang, Jiangsu province, China --SIMM-Crown Mouse Clinical Trial Center, or SCMC.

26 Nov 2013

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Agalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

26 Nov 2013

MEMREHAB Trial shows significant effect for cognitive rehabilitation in MS

Kessler Foundation researchers published the results of the MEMREHAB Trial in Neurology, the medical journal of the American Academy of Neurology, providing the first Class I evidence for the efficacy of cognitive rehabilitation in multiple sclerosis. The article, Chiaravalloti N, Moore NB, Nikelshpur OM, DeLuca D: An RCT to treat learning impairment in MS. Neurology 2013(81), was released as an epub ahead of print on November 8

22 Nov 2013

Parkinson's Institute, Population Diagnostics discover new genes relevant to Parkinson's disease

The Parkinson's Institute and Clinical Center announced today that they, in partnership with Population Diagnostics, Inc., have discovered a number of new genes relevant to the cause of Parkinson's disease.

20 Nov 2013

Mount Sinai biologist wins NIH Director's New Innovator Awards for High-Risk, High Reward Research

Arvin Dar, PhD, structural and chemical biologist in oncological sciences at the Icahn School of Medicine at Mount Sinai, is one of 41 national recipients of the prestigious National Institutes of Health (NIH) Director's New Innovator Awards for High-Risk, High Reward Research. The award will support Dar's research into Ras-dependent cancers, specifically investigating how to combat mutations in Ras, a protein implicated in at least one of every five cancers.

16 Nov 2013

Mount Sinai researchers successfully test SUMO-1 gene therapy to reverse heart failure

Researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai have successfully tested a powerful gene therapy, delivered directly into the heart, to reverse heart failure in large animal models.

14 Nov 2013

FOXO3 transcription factor may protect against alcohol-induced liver injury

New data suggest that the transcription factor FOXO3 may protect against alcohol-induced liver injury. Researchers determined that alcohol given to mice deficient in FOXO3 caused severe liver injury resembling human alcoholic hepatitis.

11 Nov 2013

Cholesterol metabolite promotes tumor growth in breast cancers

A team of researchers at UT Southwestern has found that as cholesterol is metabolized, a potent stimulant of breast cancer is created - one that fuels estrogen-receptor positive breast cancers, and that may also defeat a common treatment strategy for those cancers.

8 Nov 2013

Inhibition of heart protein reduces damage from heart attack, say researchers

The stop and start of blood flow to the heart during and after a heart attack causes severe damage to heart cells, reducing their capacity to function and potentially causing their death.

7 Nov 2013

NTU establishes new $60 million research institute in Nanomedicine

Nanyang Technological University is giving the development of nanotechnology a big boost, by establishing a new $60 million research institute in Nanomedicine, which focuses on the medical application of nanotechnology. An emerging field in drugs, nanomedicine are made up of tiny nano-sized particles thousands of times smaller than a grain of sand.

5 Nov 2013

Translation News and Research

Ribosomal proteins RPL5, RPL11 play essential role in normal cell proliferation

New Journal presents techniques for finding new uses for approved drugs

NIH data-sharing may advance genetic and translational research, therapeutic target discovery

Viewpoints: Optimism about Obamacare; 834 errors; can-you-keep-your-doctor debate

Scientists target protein-detection approach to systematically measure human repertoire of proteins

Finding identifies new mechanism that could contribute to the pathology of ALS

Study identifies high burden of pain in older adults

Enzyme intervenes when cancer-fighting PTEN is bound for cell's protein-destroying machinery

UMass Medical School licenses "anti-gal" technology to Agalimmune

Research: Human neural stem cells could improve blood flow in critical limb ischemia

SIMM and Crown Bioscience collaborate to build MCT center in China

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

MEMREHAB Trial shows significant effect for cognitive rehabilitation in MS

Parkinson's Institute, Population Diagnostics discover new genes relevant to Parkinson's disease

Mount Sinai biologist wins NIH Director's New Innovator Awards for High-Risk, High Reward Research

Mount Sinai researchers successfully test SUMO-1 gene therapy to reverse heart failure

FOXO3 transcription factor may protect against alcohol-induced liver injury

Cholesterol metabolite promotes tumor growth in breast cancers

Inhibition of heart protein reduces damage from heart attack, say researchers

NTU establishes new $60 million research institute in Nanomedicine

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News